GlaxoSmithKline plc Company Profile (LON:GSK)

About GlaxoSmithKline plc

GlaxoSmithKline plc logoGlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, respiratory and rare diseases.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: GSK
  • CUSIP:
Key Metrics:
  • Previous Close: $20.43
  • 50 Day Moving Average: $1574.31
  • 200 Day Moving Average: $1593.52
  • 52-Week Range: £48,680,000 - GBX 1,362
  • Trailing P/E Ratio: 88.15
  • P/E Growth: 1.38
  • Market Cap: $79.81B
  • Outstanding Shares: 4,868,000,000
Additional Links:

Analyst Ratings

Consensus Ratings for GlaxoSmithKline plc (LON:GSK) (?)
Ratings Breakdown: 2 Sell Ratings, 12 Hold Ratings, 9 Buy Ratings
Consensus Rating:Hold (Score: 2.30)
Consensus Price Target: GBX 1,745.45

Analysts' Ratings History for GlaxoSmithKline plc (LON:GSK)
DateFirmActionRatingPrice TargetDetails
2/22/2017Berenberg BankReiterated RatingHoldGBX 1,850View Rating Details
2/22/2017Deutsche Bank AGReiterated RatingHoldGBX 1,720View Rating Details
2/17/2017Jefferies Group LLCBoost Price TargetBuyGBX 1,780 -> GBX 1,800View Rating Details
2/16/2017Beaufort SecuritiesReiterated RatingBuyGBX 1,750View Rating Details
2/15/2017Goldman Sachs Group, Inc. (The)Set Price TargetBuyGBX 1,850View Rating Details
2/14/2017Liberum CapitalReiterated RatingBuyGBX 1,900View Rating Details
2/13/2017J P Morgan Chase & CoBoost Price TargetNeutralGBX 1,600 -> GBX 1,670View Rating Details
2/10/2017Shore CapitalReiterated RatingHoldView Rating Details
2/9/2017Credit Suisse GroupReiterated RatingNeutralGBX 1,750View Rating Details
2/9/2017HSBC Holdings plcReiterated RatingBuyGBX 1,970View Rating Details
2/6/2017Morgan StanleyReiterated RatingEqual weightGBX 1,700View Rating Details
1/15/2017BNP ParibasReiterated RatingUnderperformGBX 1,520View Rating Details
1/9/2017Bryan, Garnier & CoReiterated RatingBuyGBX 1,850View Rating Details
11/10/2016Societe GeneraleReiterated RatingSellGBX 1,320View Rating Details
11/7/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
10/27/2016NatixisReiterated RatingNeutralGBX 1,750View Rating Details
10/20/2016InvestecInitiated CoverageBuyGBX 1,925View Rating Details
10/19/2016Sanford C. BernsteinSet Price TargetNeutralGBX 1,834View Rating Details
8/4/2016Independent Research GmbHSet Price TargetNeutralGBX 1,800View Rating Details
7/27/2016S&P Global IncSet Price TargetNeutralGBX 1,650View Rating Details
7/7/2016Canaccord GenuityReiterated RatingHoldGBX 1,785View Rating Details
5/4/2016Barclays PLCBoost Price TargetOverweightGBX 1,650 -> GBX 1,670View Rating Details
3/10/2016AlphaValueReiterated RatingAddGBX 1,536View Rating Details
2/12/2016Baader BankReiterated RatingHoldGBX 1,530View Rating Details
1/28/2016Leerink SwannReiterated RatingMarket PerformGBX 1,565View Rating Details
11/17/2015JP Morgan CazenoveReiterated RatingNeutralGBX 1,370View Rating Details
11/6/2015Oddo SecuritiesReiterated RatingReduceGBX 1,360View Rating Details
10/5/2015Kepler Capital MarketsReiterated RatingHoldGBX 1,540View Rating Details
9/7/2015Bank of America CorpUpgradeNeutralView Rating Details
6/9/2015Cenkos Securities LtdReiterated RatingBuyGBX 1,643View Rating Details
5/7/2015Charles StanleyReiterated RatingaccumulateView Rating Details
(Data available from 2/26/2015 forward)


Earnings History for GlaxoSmithKline plc (LON:GSK)
No earnings announcements for this company have been tracked by


Earnings Estimates for GlaxoSmithKline plc (LON:GSK)
Current Year EPS Consensus Estimate: $110.57 EPS


Dividend History for GlaxoSmithKline plc (LON:GSK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/8/2017GBX 231.47%2/23/20172/23/20174/13/2017
10/26/2016GBX 191.17%11/3/201611/3/20161/12/2017
7/27/2016GBX 191.12%8/11/20168/11/201610/13/2016
4/27/2016GBX 191.28%5/12/20165/12/20167/14/2016
10/28/2015GBX 191.34%11/12/201511/12/20151/14/2016
10/28/2015GBX 201.34%2/18/20162/18/20164/14/2016
7/29/2015GBX 191.38%8/13/20158/13/201510/1/2015
5/6/2015GBX 191.25%5/14/20155/14/20157/9/2015
2/4/2015GBX 231.56%2/19/20152/19/20154/9/2015
10/22/2014GBX 191.37%11/6/201411/6/20141/8/2015
7/23/2014GBX 191.28%8/6/20148/6/201410/2/2014
4/30/2014GBX 191.17%5/14/20145/14/20147/10/2014
2/5/2014GBX 231.36%2/19/20142/19/20144/10/2014
10/23/2013GBX 191.15%11/13/201311/13/20131/9/2014
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for GlaxoSmithKline plc (LON:GSK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/22/2017Simon DingemansInsiderSell3,589GBX 1,640£58,859.60
2/20/2017Sir Andrew P WittyInsiderSell10,633GBX 1,634£173,743.22
2/16/2017Patrick VallanceInsiderSell32,996GBX 1,624£535,855.04
2/9/2017Victoria WhyteInsiderSell4,820GBX 1,576£75,963.20
2/8/2017Vivienne CoxInsiderBuy342GBX 1,555£5,318.10
1/11/2017Simon DingemansInsiderBuy8GBX 1,596£127.68
1/9/2017Moncef SlaouiInsiderBuy58GBX 1,972£1,143.76
12/9/2016Sir Andrew P WittyInsiderBuy8GBX 1,478£118.24
11/9/2016Victoria WhyteInsiderBuy8GBX 1,593£127.44
11/3/2016Moncef SlaouiInsiderBuy6GBX 1,937£116.22
10/27/2016Sir Andrew P WittyInsiderSell10,000GBX 1,636£163,600
10/26/2016Manvinder Singh BangaInsiderBuy1,750GBX 1,643£28,752.50
10/11/2016Simon DingemansInsiderBuy7GBX 1,728£120.96
10/7/2016Moncef SlaouiInsiderBuy4GBX 2,148GBX 8,592
9/22/2016Moncef SlaouiInsiderBuy2GBX 2,179GBX 4,358
9/9/2016Witty,Sir Andrew PInsiderBuy8GBX 1,616£129.28
8/12/2016Slaoui,MoncefInsiderBuy28GBX 2,208£618.24
8/9/2016Dingemans,SimonInsiderBuy8GBX 1,680£134.40
7/27/2016Witty,Sir Andrew PInsiderSell10,000GBX 1,693£169,300
7/11/2016Witty,Sir Andrew PInsiderBuy7GBX 1,671£116.97
7/8/2016Slaoui,MoncefInsiderBuy4GBX 2,169GBX 8,676
7/1/2016Cartwright,StaceyInsiderBuy461GBX 1,559£7,186.99
6/9/2016Dingemans,SimonInsiderBuy9GBX 1,441£129.69
5/20/2016Slaoui,MoncefInsiderBuy14GBX 2,100£294
5/12/2016Slaoui,MoncefInsiderBuy24GBX 2,103£504.72
5/11/2016Witty,Sir Andrew PInsiderBuy8GBX 1,476£118.08
4/28/2016Witty,Sir Andrew PInsiderSell10,000GBX 1,475£147,500
4/14/2016Slaoui,MoncefInsiderBuy495GBX 2,156£10,672.20
3/31/2016Anderson,Sir RoyInsiderBuy511GBX 1,405£7,179.55
3/9/2016Witty,Sir Andrew PInsiderBuy9GBX 1,404£126.36
2/15/2016Dingemans,SimonInsiderSell39,987GBX 1,406£562,217.22
2/9/2016Witty,Sir Andrew PInsiderBuy9GBX 1,369£123.21
1/28/2016Dingemans,SimonInsiderBuy684GBX 1,381£9,446.04
1/14/2016Witty,Sir Andrew PInsiderBuy43GBX 1,369£588.67
1/12/2016Dingemans,SimonInsiderBuy9GBX 1,359£122.31
12/9/2015Dingemans,SimonInsiderBuy9GBX 1,325£119.25
11/10/2015Dingemans,SimonInsiderBuy9GBX 1,366£122.94
10/12/2015Dingemans,SimonInsiderBuy10GBX 1,307£130.70
10/1/2015Rohner,UrsInsiderBuy525GBX 1,251£6,567.75
9/10/2015Witty,Sir Andrew PInsiderBuy10GBX 1,318£131.80
8/12/2015Dingemans,SimonInsiderBuy8GBX 1,443£115.44
7/10/2015Witty,Sir Andrew PInsiderBuy9GBX 1,369£123.21
7/1/2015Wijers,HansInsiderBuy534GBX 13.45GBX 7,182.30
3/31/2015Sir Christopher GentInsiderBuy3,991GBX 1,566£62,499.06
3/9/2015Moncef SlaouiInsiderSell22,274GBX 1,544£343,910.56
2/18/2015Moncef SlaouiInsiderSell1,580GBX 1,553£24,537.40
2/13/2015Simon DingemansInsiderSell12,605GBX 1,543.12£194,510.28
(Data available from 1/1/2013 forward)


Latest Headlines for GlaxoSmithKline plc (LON:GSK)
News IconInvestor Box: Viewing Levels on Shares of GlaxoSmithKline PLC (GSK) - BVN (LON:GSK) - February 25 at 5:42 AM
News IconChecking the Charts on Shares of GlaxoSmithKline PLC (GSK.L) - Rives Journal (LON:GSK) - February 24 at 10:52 AM logoGlaxoSmithKline Breaks Above 200-Day Moving Average - Bullish for GSK (LON:GSK) - February 23 at 10:32 PM
News IconInvestor Focus on Shares of GlaxoSmithKline PLC (GSK.L) - Searcy News (LON:GSK) - February 23 at 4:04 AM
News IconForward Earnings Estimate of GlaxoSmithKline PLC(GSK) - Highland Mirror (LON:GSK) - February 23 at 4:04 AM logoGLAXOSMITHKLINE PLC : ex-dividend day for final dividend (LON:GSK) - February 22 at 11:02 PM logoAnalyst Activity – Berenberg Bank Reiterates Hold on GlaxoSmithKline plc (LON:GSK) (LON:GSK) - February 22 at 1:01 PM
News IconDrug Manufacturers – Major: GlaxoSmithKline plc (NYSE:GSK) Position of the day (LON:GSK) - February 22 at 1:01 PM logo3 mega cheap FTSE 100 dividend stocks (LON:GSK) - February 22 at 1:01 PM logoDrugs-crazed shoot-out: which investment is best out of Astra, Glaxo and Shire? - Proactive Investors UK (LON:GSK) - February 18 at 12:20 PM logoCould BP plc and GlaxoSmithKline plc help you retire early? (LON:GSK) - February 17 at 4:07 PM
News IconBank of America ML Didn't Change HIV Estimates for GlaxoSmithKline plc (ADR) (GSK) - Smаrt Stоck Nеws (LON:GSK) - February 14 at 11:46 PM
News IconGlaxoSmithKline PLC (NYSE:GSK) Stock Price Target Given At $48.5 - Transcript Daily (LON:GSK) - February 14 at 6:46 PM logoGlaxoSmithKline plc (ADR)(NYSE:GSK) Two-Drug Cocktail Aims Decrease HIV Patient Pill Intake - Market Exclusive (LON:GSK) - February 14 at 6:46 PM logoGlaxoSmithKline Performance Continues, but Generic Competition May Finally Be Coming (LON:GSK) - February 14 at 3:22 PM
News IconEPS Of GlaxoSmithKline PLC (NYSE:GSK) At $0.59 - Stock Observer (LON:GSK) - February 13 at 11:39 AM
News IconWill Smith & Nephew plc Surge Past GlaxoSmithKline plc, AstraZeneca plc And Shire PLC After Full Year Results? (LON:GSK) - February 9 at 4:13 AM logoGSK Turns To Profit In Q4 - Quick Facts (LON:GSK) - February 8 at 11:13 PM logoPRESS DIGEST- British Business - Feb 9 (LON:GSK) - February 8 at 11:13 PM
News IconGlaxoSmithKline Swung to Profit in Fourth Quarter, Helped by Weak Pound -- 3rd Update (LON:GSK) - February 8 at 6:11 PM logoGlaxo braces itself for £1bn Advair hit (LON:GSK) - February 8 at 6:11 PM logoGlaxoSmithKline Plc (GSK) Q4 2016 Results - Earnings Call Transcript (LON:GSK) - February 8 at 6:11 PM
News IconGlaxoSmithKline PLC (NYSE:GSK) Equity Price Target Fixed At ... - Transcript Daily (LON:GSK) - February 6 at 10:37 PM
News IconGlaxoSmithKline PLC (NYSE:GSK) has industry P/E ratio of 29.05 - The Newburgh Press (LON:GSK) - February 6 at 10:37 PM logoGlaxoSmithKline PLC (NYSE:GSK) Mean Rating At $1.86 - (LON:GSK) - February 4 at 5:36 PM logoGSK Says New Claim Has No Evidence In Avandia MDL (LON:GSK) - February 3 at 11:04 PM logoGlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards? - Yahoo Finance (LON:GSK) - February 3 at 6:04 PM logoGlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards? (LON:GSK) - February 2 at 6:11 PM
News IconGlaxoSmithKline PLC (NYSE:GSK) Quarterly EPS Projection At $0.56 - Stock Observer (LON:GSK) - January 30 at 11:17 PM
News IconEquity In Focus: Stock Strength Indicator Watch On GlaxoSmithKline plc (NYSE:GSK) - Wall Street Beacon (LON:GSK) - January 30 at 11:17 PM logoWhat’s the Secret Ingredient in That Pizza Crust? Antacid (LON:GSK) - January 29 at 10:35 PM
News IconLeading stocks in today’s market: GlaxoSmithKline plc (NYSE:GSK) (LON:GSK) - January 28 at 5:40 PM
News IconGlaxoSmithKline PLC (NYSE:GSK) EPS Predicted At $0.74 - Transcript Daily (LON:GSK) - January 27 at 5:06 AM
News IconConsensus Take: GlaxoSmithKline PLC (NYSE:GSK) Earnings & Ratings Watch - Aiken Advocate (LON:GSK) - January 27 at 5:06 AM
News IconStock Watch: Indicators in View for GlaxoSmithKline PLC (GSK.L) - Springdale Times (LON:GSK) - January 27 at 5:06 AM
News IconThe JP Morgan Chase & Co Reiterates "Neutral" Rating for GlaxoSmithKline plc (GSK) (LON:GSK) - January 26 at 7:04 PM
News IconIs Unilever plc A Better Dividend Stock Than National Grid plc, BP plc, GlaxoSmithKline plc And Lloyds Banking Group PLC After 2016 Results? (LON:GSK) - January 26 at 7:04 PM logoGM, Nike, Microsoft Are Hot Now That Dow Has Hit 20,000 (LON:GSK) - January 26 at 7:04 PM logo11 Largest Pharmaceutical Companies In The World (LON:GSK) - January 26 at 7:04 PM logoNovartis AG -- Moody's changes outlook on Novartis' Aa3 rating to negative on share buy backs announcement; affirms ratings (LON:GSK) - January 26 at 7:04 PM logoIs GlaxoSmithKline's Dividend Sustainable? (LON:GSK) - January 26 at 7:04 PM
News IconAnalysts At Goldman Sachs Reiterated GlaxoSmithKline PLC (LON:GSK) As Buy (LON:GSK) - January 25 at 6:56 PM
News IconChart Indicator Check on Shares of GlaxoSmithKline PLC (GSK.L) - Springdale Times (LON:GSK) - January 25 at 4:22 AM logoGlaxoSmithKline Plc breached its 50 day moving average in a Bearish Manner : GSK-GB : January 24, 2017 (LON:GSK) - January 24 at 3:58 AM
News IconInvestor Lookout: Technical Indicator Watch for GlaxoSmithKline PLC (GSK.L) - Springdale Times (LON:GSK) - January 23 at 5:56 PM
News IconTraders Watch list: GlaxoSmithKline plc (NYSE:GSK), Himax Technologies, Inc. (NASDAQ:HIMX) - The Newburgh Press (LON:GSK) - January 23 at 5:56 PM logoFTSE 100 drops, as pound moves higher after Trump’s remarks (LON:GSK) - January 23 at 11:16 AM
News IconABR Of GlaxoSmithKline PLC (NYSE:GSK) At 1.86 - Stock Observer (LON:GSK) - January 22 at 10:29 PM
News IconChecking Indicator Levels for GlaxoSmithKline plc (GSK) - Rives Journal (LON:GSK) - January 22 at 5:27 PM
News IconBetter Buy: GlaxoSmithKline PLC vs. Johnson & Johnson | Fox ... - Fox Business (LON:GSK) - January 22 at 5:27 PM


What is GlaxoSmithKline plc's stock symbol?

GlaxoSmithKline plc trades on the London Stock Exchange (LON) under the ticker symbol "GSK."

How often does GlaxoSmithKline plc pay dividends? What is the dividend yield for GlaxoSmithKline plc?

GlaxoSmithKline plc announced a dividend on Wednesday, February 8th. Stockholders of record on Thursday, February 23rd will be paid a dividend of GBX 23 per share on Thursday, April 13th. This represents a dividend yield of 1.47%. The ex-dividend date of this dividend is Thursday, February 23rd. This is a positive change from GlaxoSmithKline plc's previous dividend of $19.00. The official announcement can be seen at this link.

Where is GlaxoSmithKline plc's stock going? Where will GlaxoSmithKline plc's stock price be in 2017?

23 analysts have issued 12-month target prices for GlaxoSmithKline plc's shares. Their predictions range from GBX 1,320 to GBX 1,970. On average, they expect GlaxoSmithKline plc's stock price to reach GBX 1,745.45 in the next year.

When will GlaxoSmithKline plc announce their earnings?

GlaxoSmithKline plc is scheduled to release their next quarterly earnings announcement on Tuesday, April, 25th 2017.

How do I buy GlaxoSmithKline plc stock?

Shares of GlaxoSmithKline plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

How much does a share of GlaxoSmithKline plc stock cost?

One share of GlaxoSmithKline plc stock can currently be purchased for approximately GBX 1,639.50.

Last Updated on 2/26/2017 by Staff